Merck's Capital Idea: Industry's Latest Push to Strengthen VC Ties
IN an effort to forge earlier and stronger ties to venture-backed biotechs, the new Merck Research Venture Fund illustrates the lure -- and the limitations -- of strategic pharma-VC relationships. Merck has endowed the MRVF with $250 million and the fund will make a series of investments in life science venture capital firms around the globe. Simultaneously it has also staked a second fund, the Global Health Innovation Fund, with an additional $250 million to invest in later-stage companies outside of the drug area.
You may also be interested in...
Vree Health, one of the independent subsidiaries Merck is fostering through its innovation ventures initiative, is moving into commercial phase, as it builds a business model that focuses on helping providers meet key goals of health care reform: higher quality and more cost-effective patient care.
At Elsevier Business Intelligence's recent Therapeutic Area Partnerships conference, a roundtable of senior pharmaceutical executives and entrepreneurs weighed in on industry’s current funding challenges, how dealmaking defines a biotech’s ambitions and strategy, and pharma’s appetite for early-stage innovation.
With $200 million under management and its first investment in the books, venBio is a new pharma-centric venture fund built for these strange times, when big drug companies have all the cash, all the leverage, and an insatiable need for new products.